Login to Your Account

Kala lands $22.5M to test mucous-piercing nanoparticles

By Michael Fitzhugh
Staff Writer

Thursday, April 24, 2014
Kala Pharmaceuticals Inc. has completed a $22.5 million financing to fund four trials of the company's mucous-penetrating nanoparticle platform and its lead application in fighting inflammation after cataract surgery.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription